摘要
目的:探讨利拉鲁肽联合二甲双胍治疗肥胖2型糖尿病患者临床疗效。方法:选取2015年4月至2016年4月期间汉川市人民医院收治的疗肥胖2型糖尿病患者106例作为实验对象,根据治疗方案的不同随机将患者分为对照组(n=53例)和观察组(n=53例),对照组患者采用二甲双胍治疗,观察组患者采用利拉鲁肽联合二甲双胍治疗,对比分析不同治疗方案的临床治疗效果。结果:两组患者治疗后各项指标均优于治疗前(P<0.05),组间治疗后对比,观察组各项指标均优于对照组(P<0.05);观察组不良反应发生率显著低于对照组(P<0.05)。结论:肥胖2型糖尿病患者在二甲双胍治疗的基础上增加利拉鲁肽治疗,能够有效地提高患者临床治疗效果,具有一定临床运用价值。
Objective： To explore the clinical effects of liraglutide combined with metformin in the treatment of patients with obesity type 2 diabetes. Methods： 106 patients with obesity type 2 diabetes and who accepted treatments in our hospital from April 2015 to April 2016 were selected as the experiment objects, and randomly divided into the control group（n=53 cases） and the observation group（n=53 cases） according to the different treatment plan. In the control group, they were treated with metformin, while the observation group was treated with liraglutide combined with metformin. Then, the clinical treatment effect of different treatment options were compared and analyzed. Outcome： The indexes of the two groups of patients after the treatment were better than that before the treatment（P〈0.05）. After the treatment, the indexes in the observation group were better than that in the control group（P〈0.05）; and the incidence rate of adverse reactions in the observation group was significantly lower than that in the control group（P〈0.05）. Conclusion： The increase of liraglutide treatment based on the treatment of metformin in the treatment of patients with obesity type 2 diabetes, which effectively improve the clinical treatment effect, thus it has a certain clinical application value.
出处
《药品评价》
CAS
2016年第15期23-26,共4页
Drug Evaluation
关键词
利拉鲁肽
二甲双胍
肥胖
2型糖尿病
临床疗效
Liraglutide
Metformin
Obesity
Type 2 Diabetes Mellitus
Clinical Effect
